haemophilia B Archives -

Dutch biotech uniQure and partner CSL Behring are planning to file for approval of their gene therapy for

Trial sets up filings for uniQure’s haemophilia gene therapy

https://pharmaphorum.com/news/trial-sets-up-filings-for-uniqures-haemophilia-gene-therapy/

News/ News/ R&D

Sanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issue

Phil Taylor Alnylam, Dupixent, Haematology, haemophilia A, haemophilia B, Sanofi 0 Comment

Sanofi’s much anticipated drug for both haemophilia A and B – fitusiran – could be filed in 2022

Sanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issue

https://pharmaphorum.com/news/sanofi-eyes-2022-filing-for-haemophilia-drug-fitusiran-despite-safety-issue/

News/ News/ R&D

FDA lifts hold on uniQure gene therapy after cancer case review

Phil Taylor fda, gene therapy, haemophilia B, safety, uniQure 0 Comment

Dosing can start once again in uniQure’s phase 3 trial of its haemophilia B gene therapy, after the

FDA lifts hold on uniQure gene therapy after cancer case review

https://pharmaphorum.com/news/fda-lifts-hold-on-uniqure-gene-therapy-after-cancer-case-review/

News/ News/ Sales and Marketing/ Top stories

$2bn deal sees uniQure license haemophilia B gene therapy to CSL Behring

George Underwood CSL Behring, haemophilia B, uniQure 0 Comment

UniQure has signed a deal that could be worth over $2 billion with CSL Behring – giving the

$2bn deal sees uniQure license haemophilia B gene therapy to CSL Behring

https://pharmaphorum.com/news/2bn-deal-sees-uniqure-license-haemophilia-b-gene-therapy-to-csl-behring/

News/ R&D

Pfizer moves haemophilia gene therapy into phase 3

Piotr Wnuk haemophilia, haemophilia B, Pfizer, Spark Therapeutics 0 Comment

US pharma giant Pfizer and partner Spark Therapeutics has begun a phase 3 trial of a gene therapy

Pfizer moves haemophilia gene therapy into phase 3

https://pharmaphorum.com/r-d/pfizer-haemophilia-b-gene-therapy/

News/ News/ Pfizer/ R&D/ R&D/ Rare diseases/ Top stories

Spark/Pfizer eye phase 3 trial of haemophilia B gene therapy

Richard Staines gene therapy, haemophilia B, Rare diseases 0 Comment

Spark Therapeutics has already revolutionised treatment of a rare hereditary eye disease with a gene therapy, but could

Spark/Pfizer eye phase 3 trial of haemophilia B gene therapy

https://pharmaphorum.com/news/spark-pfizers-haemophilia-b-drug-dramatically-reduces-bleeds/

M&A/ News/ News/ R&D

After losing out on two big deals, Sanofi to buy Bioverativ for $11.6bn

Richard Staines Bioverativ, haemophilia, haemophilia A, haemophilia B, Sanofi 0 Comment

French pharma makes move into haemophilia market.

After losing out on two big deals, Sanofi to buy Bioverativ for $11.6bn

https://pharmaphorum.com/news/losing-two-big-deals-sanofi-buys-bioverativ-11-6bn/

News/ R&D

‘Cure for hemophilia within reach’ as BioMarin and Spark gene therapies shine

Andrew McConaghie ASH17, BioMarin, haemophilia, haemophilia A, haemophilia B 0 Comment

While clinicians attending the American Society of Hematology meeting in Atlanta this weekend were anticipating a flurry of

‘Cure for hemophilia within reach’ as BioMarin and Spark gene therapies shine

https://pharmaphorum.com/news/cure-hemophilia-within-reach-biomarin-spark-gene-therapies-shine/

News/ R&D

Spark and Pfizer’s gene therapy wows in haemophilia B

Andrew McConaghie ASH17, haemophilia, haemophilia B, Spark Therapeutics 0 Comment

Gene therapy company Spark Therapeutics has published data showing its one-time treatment can almost entirely eliminate bleeds in

Spark and Pfizer’s gene therapy wows in haemophilia B

https://pharmaphorum.com/news/spark-pfizers-gene-therapy-wows-haemophilia-b/

Trending

haemophilia B

Login